New treatment approach for liver cancer using a special dye
Official title: Radioiodinated Indocyanine Green: A Novel Liver Cancer Therapeutic Modality
Funded at National Cancer Institute · NIH-10497368 · Data updated 2026-11-12
This study is exploring a new way to treat liver cancer by using a special dye that can deliver targeted radiation directly to the tumors, and it's designed for people who are facing liver cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Cancer Institute NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| NIH project number | 1FI2GM146602-01 |
| Project ID | NIH-10497368 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with liver cancer, particularly those with hepatocellular carcinoma or hepatoblastoma.
✕Less likely to help
Patients with liver cancer types that do not express the solute carrier transporter targeted by this treatment may not benefit.
What this research studies
This research focuses on creating a new treatment for liver cancer by developing radioiodinated versions of indocyanine green (ICG), a dye that is already approved for medical use. The researchers aim to attach a radioactive isotope to ICG, which will allow it to target liver cancer cells specifically and deliver radiation directly to the tumors. The project includes testing these new compounds in laboratory models and studying how they behave in living organisms with liver tumors. This innovative approach combines expertise in dye synthesis and cancer treatment to potentially improve outcomes for patients with liver cancer.
Why it matters
Potential benefit: If successful, this research could provide a targeted and effective treatment option for patients with liver cancer.
How similar studies have gone: Previous research has shown promising results using similar targeted approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
-
National Cancer Institute
Bethesda, United States Active
Researchers
- Principal investigator: Marker, Sierra C — National Cancer Institute
- Study coordinator: Marker, Sierra C
Related research
Other NIH-funded projects on the same topics.
-
AI-powered liver cancer screening using ultrasound blood flow patterns
A new AI-based method analyzes liver blood flow signals to help detect liver cancer early in people with liver disease, especially in settings with limited resources.
-
Aging and liver cancer: new ways to prevent and fight hepatocellular carcinoma
This research explores how aging promotes liver cancer and tests new preventive approaches that could help people at higher risk due to age.
-
Testing new therapies for pediatric and young adult sarcoma, kidney, and liver cancers
Researchers are testing new drugs and smart combinations in models of pediatric cancers to help guide future treatments for kids and young adults.
-
Liver cancer prevention and care in Uganda using HIV clinic networks
A program in Uganda uses existing HIV care systems to roll out liver cancer prevention, screening, and treatment strategies tailored to local needs.
-
Leveraging HIV care to prevent liver cancer in Uganda
A program in Uganda uses existing HIV care clinics to roll out a liver cancer prevention and treatment plan tailored to local needs.
-
Damaged telomeres and telomerase in liver scarring and liver cancer
Using human stem-cell models, researchers look at how short telomeres and telomerase changes can lead to liver scarring and liver cancer for people with telomere-related risks.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.